https://scholars.lib.ntu.edu.tw/handle/123456789/542062
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Zhou T. | en_US |
dc.contributor.author | Zhou F. | en_US |
dc.contributor.author | Guo J. | en_US |
dc.contributor.author | Shi H. | en_US |
dc.contributor.author | Yao X. | en_US |
dc.contributor.author | Guo H. | en_US |
dc.contributor.author | Yuan J. | en_US |
dc.contributor.author | Tian Y. | en_US |
dc.contributor.author | Zhang X. | en_US |
dc.contributor.author | Wang S. | en_US |
dc.contributor.author | Jiang Y. | en_US |
dc.contributor.author | Zou Q. | en_US |
dc.contributor.author | Zhou D. | en_US |
dc.contributor.author | Li H. | en_US |
dc.contributor.author | Li F. | en_US |
dc.contributor.author | Lee J.L. | en_US |
dc.contributor.author | CHUNG-HSIN CHEN | en_US |
dc.contributor.author | Park S.H. | en_US |
dc.contributor.author | Ng Q.S. | en_US |
dc.contributor.author | Ma J. | en_US |
dc.contributor.author | Zheng R. | en_US |
dc.contributor.author | Ding Q. | en_US |
dc.contributor.author | Liu X. | en_US |
dc.contributor.author | Li R. | en_US |
dc.contributor.author | Krissel H. | en_US |
dc.contributor.author | Wagner V.J. | en_US |
dc.contributor.author | Sun Y. | en_US |
dc.date.accessioned | 2021-01-26T03:36:43Z | - |
dc.date.available | 2021-01-26T03:36:43Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092455674&doi=10.1111%2fajco.13479&partnerID=40&md5=73ed9b6f5b90b6dff331a797c7278764 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/542062 | - |
dc.description.abstract | Aim: Radium-223, a targeted alpha therapy, is approved widely for the treatment of patients with metastatic castrate-resistant prostate cancer, based on a pivotal phase 3 study in predominantly white patients. We investigated the efficacy and safety of radium-223 in Asian patients with castrate-resistant prostate cancer and metastatic bone disease. Methods: This multicenter, prospective, single-arm, open-label phase 3 trial evaluated the efficacy and safety of the standard radium-223 regimen (55 kBq/kg every 4 weeks for six cycles) in patients from Asian countries. The primary endpoints were the safety and overall survival. Results: A total of 226 patients were enrolled and received at least one dose of radium-223. Median overall survival was 14.0 months (95% confidence interval [CI], 11.2–17.4). Median time to total alkaline phosphatase and prostate-specific antigen progression were 7.5 (95% CI, 6.8–7.7) and 3.6 (95% CI, 3.1–3.7) months, respectively. Median skeletal-related event-free survival was 26.0 months (95% CI, 12.6–not reached). Grade ?3 treatment-emergent adverse events were reported in 103 (46%) of 226 patients, with anemia being the most common event (34 [15%] patients). Grade ?3 drug-related treatment-emergent adverse events occurred in 39 (17%) of 226 patients. Serious treatment-emergent adverse events were reported in 65 (29%) of 226 patients. Seven (3%) patients had an adverse event leading to death; none were considered to be related to radium-223. Conclusion: The results of this study support the use of the standard radium-223 regimen for the treatment of Asian patients with castrate-resistant prostate cancer and symptomatic bone metastases. ? 2020 The Authors. Asia-Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.relation.ispartof | Asia-Pacific Journal of Clinical Oncology | - |
dc.subject | Asian patients; bone metastases; castrate-resistant prostate cancer; radium-223; targeted alpha therapy | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | radioisotope; radium; Radium-223; bone tumor; castration resistant prostate cancer; clinical trial; human; male; multicenter study; phase 3 clinical trial; prospective study; Bone Neoplasms; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium | - |
dc.title | Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/ajco.13479 | - |
dc.identifier.scopus | 2-s2.0-85092455674 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.orcid | 0000-0002-4921-5315 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。